Acquired itraconazole resistance in Aspergillus fumigatus.

The antifungal susceptibility profiles of four ASPERGILLUS: fumigatus isolates, recovered at different times from a patient treated with itraconazole for a pulmonary ASPERGILLUS: infection, were evaluated. Itraconazole MICs against two pre-treatment isolates were 0.5 mg/L, whilst two later isolates, recovered after at least 4 months of itraconazole therapy, had itraconazole MICs of >16 mg/L. In vivo susceptibilities to itraconazole and amphotericin B were tested in a murine model of disseminated aspergillosis. Treatment efficacy was evaluated by examining mortality rates and qualitative cultures of brain and kidneys. Itraconazole therapy significantly prolonged survival of mice infected with the initial isolates as compared with untreated controls. The third isolate was only partially susceptible to itraconazole in vivo, and the fourth isolate was highly resistant. The four isolates were typed by random amplified polymorphic DNA (RAPD) with four different primers. RAPD patterns obtained with each of them were identical, suggesting that the same strain was recovered over time and had acquired resistance to itraconazole.

[1]  D. Soll The Ins and Outs of DNA Fingerprinting the Infectious Fungi , 2000, Clinical Microbiology Reviews.

[2]  E. Borel,et al.  In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus. , 1999, Journal of medical microbiology.

[3]  E. Borel,et al.  In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. , 1999, The Journal of antimicrobial chemotherapy.

[4]  J. Vazquez,et al.  Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agent. , 1999, International journal of antimicrobial agents.

[5]  R Sylvester,et al.  An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. , 1998, The Journal of infection.

[6]  J. Latgé,et al.  Molecular Typing of Environmental and Patient Isolates of Aspergillus fumigatus from Various Hospital Settings , 1998, Journal of Clinical Microbiology.

[7]  J. Levron,et al.  Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation , 1998, Bone Marrow Transplantation.

[8]  T. C. White,et al.  Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance , 1998, Clinical Microbiology Reviews.

[9]  J. Rex,et al.  Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi , 1997, Journal of clinical microbiology.

[10]  J. Latgé,et al.  Genotypic characterization of sequential Aspergillus fumigatus isolates from patients with cystic fibrosis , 1996, Journal of clinical microbiology.

[11]  K. Gull,et al.  Molecular typing by random amplification of polymorphic DNA and M13 southern hybridization of related paired isolates of Aspergillus fumigatus , 1996, Journal of clinical microbiology.

[12]  E. Johnson,et al.  Azole drug resistance in yeasts. , 1995, The Journal of antimicrobial chemotherapy.

[13]  E. Anaissie,et al.  Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi , 1995, Antimicrobial agents and chemotherapy.

[14]  N. Georgopapadakou,et al.  Human mycoses: drugs and targets for emerging pathogens. , 1994, Science.

[15]  J. Latgé,et al.  Use of DNA moderately repetitive sequence to type Aspergillus fumigatus isolates from aspergilloma patients. , 1994, The Journal of infectious diseases.

[16]  J. Burnie,et al.  Application of polymerase chain reaction to fingerprinting Aspergillus fumigatus by random amplification of polymorphic DNA , 1993, Journal of clinical microbiology.

[17]  D. Holden,et al.  Use of randomly amplified polymorphic DNA markers to distinguish isolates of Aspergillus fumigatus , 1992, Journal of clinical microbiology.

[18]  D. Denning,et al.  DNA fingerprinting of Aspergillus fumigatus isolates from patients with aspergilloma. , 1991, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[19]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[20]  C. Terrell Antifungal agents. Part II. The azoles. , 1999, Mayo Clinic proceedings.

[21]  J. Meis,et al.  Resistance of aspergillus fumigatus to itraconazole. , 1998, Scandinavian journal of infectious diseases.

[22]  E. Chryssanthou In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. acquired resistance to itraconazole. , 1997, Scandinavian journal of infectious diseases.

[23]  D. Denning Diagnosis and management of invasive aspergillosis. , 1996, Current clinical topics in infectious diseases.

[24]  D. Warnock,et al.  Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. , 1988, The Journal of antimicrobial chemotherapy.